<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296646</url>
  </required_header>
  <id_info>
    <org_study_id>09-0939</org_study_id>
    <secondary_id>1R21AA017503-01A2</secondary_id>
    <nct_id>NCT01296646</nct_id>
  </id_info>
  <brief_title>Sweet Preference and Alcohol Craving</brief_title>
  <acronym>SweetNal</acronym>
  <official_title>Sweet Preference and Alcohol Craving Predict Naltrexone Response in Alcoholism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The proposed 2-year investigation will be the first double-blind, placebo-controlled
      trial examining the hedonic response to sweet taste (HRST) as a phenotypic predictor of
      naltrexone (NTX) response in alcohol dependence. HRST yields two primary phenotypesâ€”Sweet
      Likers (SL) and Sweet Dislikers (SDL). Based on preliminary findings, HRST will be examined
      in conjunction with craving for alcohol to assess whether the two factors together provide a
      more robust predictor of NTX response. The identification of methods to predict naltrexone
      response in alcohol dependence is an important goal for alcohol treatment research. Currently
      naltrexone is not being used nearly as much as it should be, in part because clinicians do
      not believe it is very effective. The development of tools that would identify which patients
      are more likely to have a robust response to naltrexone should lead to increased use of the
      medication. This could help many patients who are not now having the opportunity of trying
      naltrexone.

      There are two principal Specific Aims for the study:

      Specific Aim 1. To test the hypothesis that a combination of SL/SDL status and initial
      alcohol craving will predict % abstinent days (%ABST) during treatment with naltrexone.

      Specific Aim 2. To test whether a combination of SL/SDL status and initial alcohol craving
      predict % heavy drinking days (%HDD) during treatment with naltrexone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants: There will be 130 alcohol-dependent individuals between 18 and 65 years of age
      recruited to participate in this randomized placebo-controlled clinical trial. Eighty
      alcohol-dependent individuals will be randomized into the study and we are allowing for 50
      screen failures. Participation in this study will be an alternative to standard treatment.
      Subjects will be blindly assessed for SL/SDL status to yield 50% representation of each
      trait.

      Procedures (methods): Subjects who meet general inclusion/exclusion criteria based on the
      screening interview will complete a sweet taste assessment. Results, along with craving
      score, will be given to the Investigational Drug Services for randomization purposes. The
      study is a double-blind, randomized, placebo-controlled clinical trial in which participants
      will receive 50 mg oral naltrexone or matching placebo for a 12-week period. In addition
      participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions
      Medical monitoring will also be conducted by study physicians and will consist of review of
      vital signs, concomitant medication use, and general inquiries into side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Heavy Drinking Days</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of heavy drinking days as derived from the Timeline Follow-back (TLFB) for the entire medication period. A heavy drinking day is defined as 5 or more standard drinks for a man and 4 or more standard drinks for a woman. A standard drink is 12-14 grams of ethanol or the amount contained in a 12 oz beer, 5 oz of wine or 1 1/2 oz of hard liquor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Days Abstinent</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of abstinence days as derived from the Timeline Follow-Back (TLFB) for the entire medication period.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sweet Liker, High Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sweet Liker - Low Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sweet Disliker - High Craver. Half of this group will be on naltrexone the other half will be on Placebo. All subjects will receive Brenda Therapy Sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sweet Disliker - Low Craver; half of this group will be on naltrexone the other half on placebo. All subjects will receive Brenda Therapy Sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>50 mg oral naltrexone once/day</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <other_name>Revia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brenda Therapy Sessions</intervention_name>
    <description>participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <other_name>Counselling</other_name>
    <other_name>Therapy Sessions</other_name>
    <other_name>Medical Management</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>An inactive pill to control for non-pharmacological responses.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <other_name>&quot;Sugar pill&quot;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women between the ages of 18 and 65 meeting DSM-IV criteria for current
             alcohol dependence.

          2. More than 14 drinks (women) or 21 drinks (men) per week including at least 2 heavy
             drinking days/week on average (men &gt; 5 drinks/day; women &gt; 4 drinks/day) during a
             consecutive 30-day period within the 90 days prior to screening.

          3. Ability to understand and sign written informed consent.

          4. Must have a 0.0 gms/dL breathalyzer reading on the day of screening and 0.0 gms/dL on
             the day of randomization.

          5. Must be willing to refrain from drinking for three days prior to randomization day.

          6. Express a desire to achieve abstinence or to greatly reduce alcohol consumption.

          7. Must have a stable residence and be able to identify an individual who could locate
             subject if needed.

        Exclusion Criteria:

          1. Clinically significant medical disease that might interfere with the evaluation of the
             study medication or present a safety concern (e.g., cirrhosis, unstable hypertension,
             seizure disorder, use of opiate medication).

          2. Clinically significant psychiatric illness including: any psychotic disorder, bipolar
             disorder, severe depression, or suicidal ideation.

          3. Other substance abuse or dependence disorder other than nicotine or alcohol.

          4. Concurrent use of any psychotropic medication including antidepressants, mood
             stabilizers, antipsychotics, anxiolytics, stimulants, or hypnotics with the exception
             of stable doses of antidepressants for one month.

          5. History of complicated alcohol withdrawal, i.e. withdrawal seizure or delirium
             tremens.

          6. AST, or ALT &gt; 3 times Upper Limit of Normal (ULN) or bilirubin &gt; ULN.

          7. Positive urine toxicology screen with the exception of cannabis. Individuals with
             positive cannabis screens will be excluded only if they have a history of cannabis
             dependence.

          8. Pregnant women and women of childbearing potential who do not practice a medically
             acceptable form of birth control (oral or depot contraceptive, or barrier methods such
             as diaphragm or condom with spermicidal) and women who are breast feeding.

          9. Individuals requiring inpatient treatment or more intense outpatient treatment for
             their alcohol dependence.

         10. Participation in any clinical trial within the past 60 days.

         11. Court-mandated participation in alcohol treatment or pending incarceration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C Garbutt, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <results_first_submitted>August 12, 2013</results_first_submitted>
  <results_first_submitted_qc>October 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2013</results_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>James Garbutt, MD</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Alcoholics</keyword>
  <keyword>Substance Abuse</keyword>
  <keyword>Alcohol Abuse</keyword>
  <keyword>Alcohol Addiction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occured primarily via community advertising by radio.</recruitment_details>
      <pre_assignment_details>Subjects were screened and, if met criteria, randomized to placebo or naltrexone generally within 5-10 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo taken once daily.</description>
        </group>
        <group group_id="P2">
          <title>Naltrexone</title>
          <description>50 mg of naltrexone orally daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo taken once daily.</description>
        </group>
        <group group_id="B2">
          <title>Naltrexone</title>
          <description>50 mg of naltrexone orally daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.3" spread="8.4"/>
                    <measurement group_id="B2" value="45.8" spread="8.6"/>
                    <measurement group_id="B3" value="47.0" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Heavy Drinking Days</title>
        <description>Percentage of heavy drinking days as derived from the Timeline Follow-back (TLFB) for the entire medication period. A heavy drinking day is defined as 5 or more standard drinks for a man and 4 or more standard drinks for a woman. A standard drink is 12-14 grams of ethanol or the amount contained in a 12 oz beer, 5 oz of wine or 1 1/2 oz of hard liquor.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo taken once daily.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone</title>
            <description>50 mg of naltrexone orally daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Heavy Drinking Days</title>
          <description>Percentage of heavy drinking days as derived from the Timeline Follow-back (TLFB) for the entire medication period. A heavy drinking day is defined as 5 or more standard drinks for a man and 4 or more standard drinks for a woman. A standard drink is 12-14 grams of ethanol or the amount contained in a 12 oz beer, 5 oz of wine or 1 1/2 oz of hard liquor.</description>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sweet Liker - High Craving n=9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.18"/>
                    <measurement group_id="O2" value="0.14" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweet Liker - Low Craving n=13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.12"/>
                    <measurement group_id="O2" value="0.17" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweet Disliker - High Craving n=31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.23"/>
                    <measurement group_id="O2" value="0.16" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweet Disliker - Low Craving n=27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.22"/>
                    <measurement group_id="O2" value="0.14" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Days Abstinent</title>
        <description>Percentage of abstinence days as derived from the Timeline Follow-Back (TLFB) for the entire medication period.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo taken once daily.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone</title>
            <description>50 mg of naltrexone orally daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Days Abstinent</title>
          <description>Percentage of abstinence days as derived from the Timeline Follow-Back (TLFB) for the entire medication period.</description>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sweet Liker - High Craving n=9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.20"/>
                    <measurement group_id="O2" value="0.77" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweet Liker - Low Craving n=13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.16"/>
                    <measurement group_id="O2" value="0.67" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweet Disliker - High Craving n=31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.27"/>
                    <measurement group_id="O2" value="0.62" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweet Disliker - Low Craving n=27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.34"/>
                    <measurement group_id="O2" value="0.66" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Subjects were asked at each visit if they had experienced any adverse events since prior visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo taken once daily.</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone</title>
          <description>50 mg of naltrexone orally daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James C. Garbutt, M.D., Professor of Psychiatry</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-966-4652</phone>
      <email>jc_garbutt@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

